ACUR — Acura Pharmaceuticals Share Price
Last Trade - 00:00- $34.30m
- $40.48m
- $3.12m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.46 | 2.97 | 0.41 | 2.66 | 3.57 | n/a | n/a | -16.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
Directors
- Robert Jones CEO (61)
- Peter Clemens CFO (67)
- Robert Seiser VPR (56)
- Albert Brzeczko VPR (63)
- James Emigh VPR (64)
- George Ross (78)
- William Skelly IND (69)
- Immanuel Thangaraj (49)
- Bruce Wesson (77)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- April 10th, 1935
- Public Since
- September 12th, 2000
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 65,089,043
- Address
- 616 N North Ct Ste 120, PALATINE, 60067-8121
- Web
- http://acurapharm.com/
- Phone
- +1 8477057709
- Contact
- Peter Clemens
- Auditors
- BDO USA, LLP
Latest News for ACUR
Upcoming events for ACUR
Similar to ACUR
AINOS ORD
Pink Sheets on Nasdaq
ALTEROLA BIOTECH ORD
Pink Sheets on Nasdaq
ANTHERA PHARMACEUTICALS ORD
Pink Sheets on Nasdaq
BASSLINE PRODUCTIONS ORD
Pink Sheets on Nasdaq
BETTERLIFE PHARMA ORD
Pink Sheets on Nasdaq
FAQ
As of Today at 19:56 UTC, shares in Acura Pharmaceuticals are trading at $0.53. This share price information is delayed by 15 minutes.
Shares in Acura Pharmaceuticals last closed at $0.53 and the price had moved by +81.72% over the past 365 days. In terms of relative price strength the Acura Pharmaceuticals share price has outperformed the S&P500 Index by +40.58% over the past year.
There is no consensus recommendation for this security.
Acura Pharmaceuticals does not currently pay a dividend.
Acura Pharmaceuticals does not currently pay a dividend.
Acura Pharmaceuticals does not currently pay a dividend.
To buy shares in Acura Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.53, shares in Acura Pharmaceuticals had a market capitalisation of $34.30m.
Here are the trading details for Acura Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ACUR
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Acura Pharmaceuticals does not currently have a style classification.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acura Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +28.62%.
As of the last closing price of $0.53, shares in Acura Pharmaceuticals were trading +40.53% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acura Pharmaceuticals.
Acura Pharmaceuticals' management team is headed by:
- Robert Jones - CEO
- Peter Clemens - CFO
- Robert Seiser - VPR
- Albert Brzeczko - VPR
- James Emigh - VPR
- George Ross -
- William Skelly - IND
- Immanuel Thangaraj -
- Bruce Wesson -
We do not have data on Acura Pharmaceuticals' shareholders